Description: OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Home Page: www.okyopharma.com
14/15 Conduit St
London,
W1S 2XJ
United Kingdom
Phone:
44 20 7495 2379
Officers
| Name | Title |
|---|---|
| Dr. Gary S. Jacob Ph.D. | CEO & Exec. Director |
| Mr. Michael Paul Beck | Founder |
| Ms. Keeren Shah | Chief Financial Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Operating Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 14.9158 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 8 |